PAS
AMGN icon

Park Avenue Securities’s Amgen AMGN Stock Holding History

Park Avenue Securities’s Portfolio AMGN Stock Details AMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1M Sell
27,835
-202
-0.7% -$69.1K 0.06% 237
2026
Q1 		$9.87M Sell
28,037
-2,968
-10% -$1.06M 0.08% 198
2025
Q4 		$10.1M Buy
31,005
+536
+2% +$170K 0.09% 185
2025
Q3 		$8.6M Sell
30,469
-597
-2% -$173K 0.07% 217
2025
Q2 		$8.67M Sell
31,066
-7,998
-20% -$2.27M 0.08% 184
2025
Q1 		$12.2M Buy
39,064
+4,320
+12% +$1.28M 0.15% 90
2024
Q4 		$9.06M Buy
34,744
+3,340
+11% +$991K 0.09% 149
2024
Q3 		$10.1M Sell
31,404
-3,767
-11% -$1.23M 0.11% 124
2024
Q2 		$11M Buy
35,171
+3,521
+11% +$1.03M 0.13% 111
2024
Q1 		$9M Buy
31,650
+353
+1% +$103K 0.12% 128
2023
Q4 		$9.01M Buy
31,297
+1,759
+6% +$479K 0.12% 109
2023
Q3 		$7.94M Buy
29,538
+4,660
+19% +$1.16M 0.12% 109
2023
Q2 		$5.52M Sell
24,878
-227
-0.9% -$52.7K 0.09% 151
2023
Q1 		$6.07M Buy
25,105
+998
+4% +$245K 0.1% 126
2022
Q4 		$6.33M Buy
24,107
+1,366
+6% +$366K 0.11% 114
2022
Q3 		$5.13M Buy
22,741
+1,838
+9% +$446K 0.1% 123
2022
Q2 		$5.09M Buy
20,903
+1,328
+7% +$325K 0.1% 126
2022
Q1 		$4.73M Buy
19,575
+12,437
+174% +$2.86M 0.08% 132
2021
Q4 		$1.61M Buy
7,138
+281
+4% +$59.3K 0.03% 320
2021
Q3 		$1.46M Buy
6,857
+114
+2% +$26.2K 0.03% 300
2021
Q2 		$1.64M Buy
6,743
+381
+6% +$93.7K 0.03% 261
2021
Q1 		$1.58M Buy
6,362
+135
+2% +$32.2K 0.04% 239
2020
Q4 		$1.43M Sell
6,227
-78
-1% -$18K 0.04% 206
2020
Q3 		$1.6M Buy
6,305
+239
+4% +$59.2K 0.05% 153
2020
Q2 		$1.43M Buy
6,066
+290
+5% +$66.2K 0.05% 148
2020
Q1 		$1.17M Buy
5,776
+1,466
+34% +$320K 0.1% 76
2019
Q4 		$1.04M Buy
4,310
+1,244
+41% +$274K 0.04% 174
2019
Q3 		$593K Sell
3,066
-76
-2% -$14.6K 0.03% 221
2019
Q2 		$579K Sell
3,142
-4,063
-56% -$728K 0.06% 109
2019
Q1 		$1.38M Buy
+7,205
New +$1.38M 0.08% 95
2017
Q3 		– Sell
-1,398
Closed -$248K – 120
2017
Q2 		$248K Buy
+1,398
New +$227K 0.03% 167

Other funds holding AMGN

Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
FFM
Forum Financial Management Lombard, Illinois $7.79B AUM 20.38% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
SP
Sarasin & Partners London, United Kingdom $8.54B AUM 9.6% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

Park Avenue Securities's AMGN Position: Q2 2026 in Review

Park Avenue Securities reduced its Amgen (AMGN) stake by 0.72% in Q2 2026, selling an estimated $69.1K and leaving 27,835 shares worth $10.1M. The position accounts for 0.06% of the portfolio, ranked #237.

Park Avenue Securities first reported a position in AMGN in Q2 2017 and has held it in 31 quarters since. The position peaked at $12.2M in Q1 2025. 1,262 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Park Avenue Securities held 27,835 shares of Amgen worth $10.1M as of Q2 2026.
  • Park Avenue Securities sold 202 Amgen shares in Q2 2026, an estimated $69.1K.
  • Amgen made up 0.06% of Park Avenue Securities's portfolio in Q2 2026, its #237 holding.
  • Park Avenue Securities first reported a position in Amgen in Q2 2017 and has held it in 31 quarters since.
  • Park Avenue Securities's Amgen position peaked at $12.2M in Q1 2025.
  • 1,262 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.